Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.License Agreement • August 14th, 2020 • Larimar Therapeutics, Inc. • Pharmaceutical preparations
Reference is made to that certain License Agreement dated as of November 30, 2016 (the “Agreement”) and an Amendment to such License Agreement dated November 28, 2017 (the “Amendment No. 1”), by and among Chondrial Therapeutics IP, LLC and Wake Forest University Health Sciences.
November 28, 2017License Agreement • August 14th, 2020 • Larimar Therapeutics, Inc. • Pharmaceutical preparations
(i)that certain License Agreement dated as of November 30, 2016 (the “Agreement”), by and among Chondrial Therapeutics IP Holdings, LLC (f/k/a Chondrial Therapeutics, LLC) and Wake Forest University Health Sciences.
LICENSE AGREEMENTLicense Agreement • August 14th, 2020 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • North Carolina
This License Agreement (the “Agreement”) is effective as of this 30th day of November, 2016 (the “Effective Date”) between Wake Forest University Health Sciences, having its principal offices at Medical Center Boulevard, Winston-Salem, North Carolina 27157 (“WFUHS”) and Chondrial Therapeutics IP Holdings, LLC (f/k/a Chondrial Therapeutics, LLC), having its principal offices at 4500 East 75th Street, Indianapolis, Indiana 46250 (“Chondrial”).
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • August 14th, 2020 • Larimar Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment (the “First Amendment”) is made and entered into as of August 16, 2019 (the “First Amendment Effective Date”) by and between:
LICENSE AGREEMENTLicense Agreement • August 14th, 2020 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • Indiana
This License Agreement (the “Agreement”) is effective as of this 30th day of November, 2016 (the “Effective Date”) between Indiana University Research and Technology Corporation, having a place of business at 518 Indiana Avenue, Indianapolis, Indiana 46202 (“IURTC”) and Chondrial Therapeutics IP Holdings, LLC (f/k/a Chondrial Therapeutics, LLC), having its principal offices at 4500 East 75th Street, Indianapolis, Indiana 46250 (“Chondrial”).
